TapImmune appoints David Laskow-Pooley to board
This article was originally published in Scrip
Executive Summary
TapImmune, an immunotherapy company specializing in the development of therapies for cancer and infectious disease, has appointed David Laskow-Pooley to its board of directors. Mr Laskow-Pooley is currently CEO of London Pharma, a clinical-stage company re-purposing approved drugs through novel drug delivery technologies, and is the co-founder of Pharmafor. He was formerly managing director (UK) of Nasdaq-listed drug discovery platform company, OSI, and was part of the corporate team that developed and launched Tarceva for the treatment of lung cancer with marketing partners Roche and Genentech.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.